{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,3]],"date-time":"2026-07-03T13:33:23Z","timestamp":1783085603130,"version":"3.54.6"},"reference-count":63,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,11,1]],"date-time":"2020-11-01T00:00:00Z","timestamp":1604188800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000071","name":"National Institute of Child Health and Human Development","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000071","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","jaacap.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"published-print":{"date-parts":[[2020,11]]},"DOI":"10.1016\/j.jaac.2019.10.013","type":"journal-article","created":{"date-parts":[[2019,11,2]],"date-time":"2019-11-02T10:26:25Z","timestamp":1572690385000},"page":"1240-1251","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":54,"title":["Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis"],"prefix":"10.1016","volume":"59","author":[{"given":"Jeffrey A.","family":"Mills","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey R.","family":"Strawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jaac.2019.10.013_bib1","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1056\/NEJMoa0804633","article-title":"Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety","volume":"359","author":"Walkup","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2019.10.013_bib2","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1002\/da.22329","article-title":"Efficacy and tolerability of antidepressants in pediatric anxiety disorders: a systematic review and meta-analysis","volume":"32","author":"Strawn","year":"2015","journal-title":"Depress Anxiety"},{"key":"10.1016\/j.jaac.2019.10.013_bib3","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1056\/NEJM200104263441703","article-title":"Fluvoxamine for the treatment of anxiety disorders in children and adolescents. The Research Unit on Pediatric Psychopharmacology Anxiety Study Group","volume":"344","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jaac.2019.10.013_bib4","doi-asserted-by":"crossref","first-page":"1969","DOI":"10.1001\/jama.292.16.1969","article-title":"Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial","volume":"292","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.10.013_bib5","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1097\/00004583-199804000-00016","article-title":"Sertraline treatment of children and adolescents with obsessive-compulsive disorder or depression: pharmacokinetics, tolerability, and efficacy","volume":"37","author":"Alderman","year":"1998","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib6","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.16m11415","article-title":"Treating pediatric anxiety: initial use of SSRIs and other antianxiety prescription medications","volume":"79","author":"Bushnell","year":"2018","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib7","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jaac.2015.01.008","article-title":"A\u00a0randomized, placebo-controlled study of duloxetine for the treatment of children and adolescents with generalized anxiety disorder","volume":"54","author":"Strawn","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib8","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1176\/ajp.2007.164.2.290","article-title":"Efficacy and safety of extended-release venlafaxine in the treatment of generalized anxiety disorder in children and adolescents: two placebo-controlled trials","volume":"164","author":"Rynn","year":"2007","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib9","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1176\/appi.ajp.158.12.2008","article-title":"Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder","volume":"158","author":"Rynn","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib10","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1016\/j.biopsych.2007.02.025","article-title":"Randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder","volume":"62","author":"March","year":"2007","journal-title":"Biol Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib11","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1111\/j.1469-7610.2007.01875.x","article-title":"Meta-analysis of randomized, controlled treatment trials for pediatric obsessive-compulsive disorder","volume":"49","author":"Watson","year":"2008","journal-title":"J\u00a0Child Psychol Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib12","doi-asserted-by":"crossref","first-page":"1919","DOI":"10.1176\/appi.ajp.160.11.1919","article-title":"Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder","volume":"160","author":"Geller","year":"2003","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib13","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1001\/jamapsychiatry.2017.2432","article-title":"Efficacy and safety of selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, and placebo in common psychiatric disorders: a meta-analysis in children and adolescents","volume":"74","author":"Locher","year":"2017","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib14","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jaac.2018.01.015","article-title":"The Impact of antidepressant dose and class on treatment response in pediatric anxiety disorders: a meta-analysis","volume":"57","author":"Strawn","year":"2018","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib15","doi-asserted-by":"crossref","DOI":"10.4088\/JCP.17r12064","article-title":"Efficacy and tolerability of pharmacotherapy in pediatric anxiety disorders: a network meta-analysis","volume":"80","author":"Dobson","year":"2019","journal-title":"J\u00a0Clin Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib16","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1001\/jamapediatrics.2017.3036","article-title":"Comparative effectiveness and safety of cognitive behavioral therapy and pharmacotherapy for childhood anxiety disorders: a systematic review and meta-analysis","volume":"171","author":"Wang","year":"2017","journal-title":"JAMA Pediatr"},{"key":"10.1016\/j.jaac.2019.10.013_bib17","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1016\/j.jaac.2016.07.768","article-title":"Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors and clomipramine in pediatric obsessive-compulsive disorder","volume":"55","author":"Varigonda","year":"2016","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib18","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1176\/appi.ajp.2008.08020247","article-title":"Placebo response in randomized controlled trials of antidepressants for pediatric major depressive disorder","volume":"166","author":"Bridge","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib19","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/S0140-6736(16)30385-3","article-title":"Comparative efficacy and tolerability of antidepressants for major depressive disorder in children and adolescents: a network meta-analysis","volume":"388","author":"Cipriani","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.jaac.2019.10.013_bib20","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1089\/cap.2008.040","article-title":"Activation adverse events induced by the selective serotonin reuptake inhibitor fluvoxamine in children and adolescents","volume":"19","author":"Reinblatt","year":"2009","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.10.013_bib21","first-page":"50","article-title":"Antidepressant-induced activation in children and adolescents: risk, recognition and management","volume":"48","author":"Luft","year":"2018","journal-title":"Curr Probl Pediatr Adolesc Health Care"},{"key":"10.1016\/j.jaac.2019.10.013_bib22","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1089\/cap.2006.16.159","article-title":"Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents","volume":"16","author":"Safer","year":"2006","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.10.013_bib23","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.jaac.2014.12.015","article-title":"Child\/adolescent anxiety multimodal study: evaluating safety","volume":"54","author":"Rynn","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib24","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1001\/archpsyc.61.11.1153","article-title":"A\u00a0multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder","volume":"61","author":"Wagner","year":"2004","journal-title":"Arch Gen Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib25","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1016\/j.jpsychires.2015.10.006","article-title":"Side-effects of SSRIs disrupt multimodal treatment for pediatric OCD in a randomized-controlled trial","volume":"71","author":"Reid","year":"2015","journal-title":"J\u00a0Psychiatr Res"},{"key":"10.1016\/j.jaac.2019.10.013_bib26","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1089\/cap.2018.0145","article-title":"Switching selective serotonin reuptake inhibitors in adolescents with selective serotonin reuptake inhibitor-resistant major depressive disorder: balancing tolerability and efficacy","volume":"29","author":"Strawn","year":"2019","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.10.013_bib27","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/01.chi.0000246070.23695.06","article-title":"Practice parameter for the assessment and treatment of children and adolescents with anxiety disorders","volume":"46","author":"Connolly","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib28","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1001\/jama.2017.15574","article-title":"Bayesian analysis: using prior information to interpret the results of clinical trials","volume":"318","author":"Quintana","year":"2017","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.10.013_bib29","doi-asserted-by":"crossref","first-page":"2208","DOI":"10.1001\/jama.2018.16916","article-title":"Time for clinicians to embrace their inner bayesian?","volume":"320","author":"Lewis","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.10.013_bib30","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1007\/s11222-013-9416-2","article-title":"Understanding predictive information criteria for Bayesian models","volume":"24","author":"Gelman","year":"2014","journal-title":"Stat Comput"},{"key":"10.1016\/j.jaac.2019.10.013_bib31","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1001\/jama.2018.17977","article-title":"Bayesian hierarchical models","volume":"320","author":"McGlothlin","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.10.013_bib32","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.jaac.2015.05.004","article-title":"Systematic review and meta-analysis: early treatment responses of selective serotonin reuptake inhibitors in pediatric major depressive disorder","volume":"54","author":"Varigonda","year":"2015","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib33","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1097\/00004583-199211000-00011","article-title":"Double-blind, crossover trial of fluoxetine and placebo in children and adolescents with obsessive-compulsive disorder","volume":"31","author":"Riddle","year":"1992","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib34","doi-asserted-by":"crossref","first-page":"99","DOI":"10.3389\/fphar.2019.00099","article-title":"Influence of CYP2C19 metabolizer status on escitalopram\/citalopram tolerability and response in youth with anxiety and depressive disorders","volume":"10","author":"Aldrich","year":"2019","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.jaac.2019.10.013_bib35","unstructured":"Mills JA, Strawn JR. Probabilistic biostatistics with Julia. In: JuliaCon Proceedings; 2019:1\u20136. Baltimore, Maryland, July 2019."},{"key":"10.1016\/j.jaac.2019.10.013_bib36","series-title":"Doing Bayesian Data Analysis: A Tutorial with R, JAGS, and Stan","author":"Kruschke","year":"2014"},{"key":"10.1016\/j.jaac.2019.10.013_bib37","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jaac.2019.10.013_bib38","doi-asserted-by":"crossref","first-page":"1158","DOI":"10.1093\/ije\/dyn204","article-title":"Commentary: Heterogeneity in meta-analysis should be expected and appropriately quantified","volume":"37","author":"Higgins","year":"2008","journal-title":"Int J Epidemiol"},{"key":"10.1016\/j.jaac.2019.10.013_bib40","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1137\/141000671","article-title":"Julia: a fresh approach to numerical computing","volume":"59","author":"Bezanson","year":"2017","journal-title":"SIAM Review"},{"key":"10.1016\/j.jaac.2019.10.013_bib41","first-page":"1682","article-title":"Turing: a language for flexible probabilistic inference","volume":"84","author":"Ge","year":"2018","journal-title":"Proc Twenty-First Int Conf Artif Intell Stat"},{"key":"10.1016\/j.jaac.2019.10.013_bib42","unstructured":"Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. http:\/\/www.handbook.cochrane.org\/."},{"key":"10.1016\/j.jaac.2019.10.013_bib43","doi-asserted-by":"crossref","first-page":"264","DOI":"10.7326\/0003-4819-151-4-200908180-00135","article-title":"PRISMA Group. Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement","volume":"151","author":"Moher","year":"2009","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jaac.2019.10.013_bib44","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1097\/01.CHI.0000037049.04952.9F","article-title":"Fluoxetine for the treatment of childhood anxiety disorders","volume":"42","author":"Birmaher","year":"2003","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib45","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1097\/chi.0b013e318154bb57","article-title":"SET-C versus fluoxetine in the treatment of childhood social phobia","volume":"46","author":"Beidel","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib46","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1097\/00004583-200107000-00011","article-title":"Fluoxetine treatment for obsessive-compulsive disorder in children and adolescents: a placebo-controlled clinical trial","volume":"40","author":"Geller","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib47","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1089\/cap.2012.0110","article-title":"Comparison among clomipramine, fluoxetine, and placebo for the treatment of anxiety disorders in children and adolescents","volume":"23","author":"da Costa","year":"2013","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.10.013_bib48","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1097\/00004583-200102000-00017","article-title":"Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial","volume":"40","author":"Riddle","year":"2001","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib49","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1097\/01.chi.0000138356.29099.f1","article-title":"Paroxetine treatment in children and adolescents with obsessive-compulsive disorder: a randomized, multicenter, double-blind, placebo-controlled trial","volume":"43","author":"Geller","year":"2004","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib50","doi-asserted-by":"crossref","first-page":"1752","DOI":"10.1001\/jama.280.20.1752","article-title":"Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial","volume":"280","author":"March","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.10.013_bib51","doi-asserted-by":"crossref","first-page":"1683","DOI":"10.1001\/jama.297.15.1683","article-title":"Clinical response and risk for reported suicidal ideation and suicide attempts in pediatric antidepressant treatment: a meta-analysis of randomized controlled trials","volume":"297","author":"Bridge","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.jaac.2019.10.013_bib52","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1007\/s10578-013-0410-x","article-title":"Somatic complaints in anxious youth","volume":"45","author":"Crawley","year":"2014","journal-title":"Child Psychiatry Hum Dev"},{"key":"10.1016\/j.jaac.2019.10.013_bib53","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1097\/01.chi.0000242233.06011.8e","article-title":"Sleep-related problems among children and adolescents with anxiety disorders","volume":"46","author":"Alfano","year":"2007","journal-title":"J\u00a0Am Acad Child Adolesc Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib54","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1080\/15374416.2015.1063429","article-title":"Sleep-related problems and the effects of anxiety treatment in children and adolescents","volume":"46","author":"Caporino","year":"2017","journal-title":"J\u00a0Clin Child Adolesc Psychol"},{"key":"10.1016\/j.jaac.2019.10.013_bib55","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.janxdis.2011.04.004","article-title":"Objective sleep patterns and severity of symptoms in pediatric obsessive compulsive disorder: a pilot investigation","volume":"25","author":"Alfano","year":"2011","journal-title":"J\u00a0Anxiety Disord"},{"key":"10.1016\/j.jaac.2019.10.013_bib56","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1016\/j.janxdis.2007.09.003","article-title":"Sleep-related problems in pediatric obsessive-compulsive disorder","volume":"22","author":"Storch","year":"2008","journal-title":"J\u00a0Anxiety Disord"},{"key":"10.1016\/j.jaac.2019.10.013_bib57","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.sleep.2018.12.024","article-title":"Insomnia in pediatric obsessive\u2013compulsive disorder: prevalence and association with multimodal treatment outcomes in a naturalistic clinical setting","volume":"56","author":"Sevilla-Cerme\u00f1o","year":"2019","journal-title":"Sleep Med"},{"key":"10.1016\/j.jaac.2019.10.013_bib58","article-title":"Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports","volume":"352","author":"Sharma","year":"2016","journal-title":"BMJ"},{"key":"10.1016\/j.jaac.2019.10.013_bib59","doi-asserted-by":"crossref","first-page":"418","DOI":"10.1176\/appi.ajp.2008.08070976","article-title":"Predictors of spontaneous and\u00a0systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study","volume":"166","author":"Brent","year":"2009","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.jaac.2019.10.013_bib60","series-title":"Bayesian Nets and Causality: Philosophical and Computational Foundations","author":"Williamson","year":"2005"},{"key":"10.1016\/j.jaac.2019.10.013_bib61","first-page":"165","volume":"Vol 2","author":"Andrews","year":"2017"},{"key":"10.1016\/j.jaac.2019.10.013_bib62","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1089\/cap.2016.0198","article-title":"Placebo response in pediatric anxiety disorders: results from the Child\/Adolescent Anxiety Multimodal Study","volume":"27","author":"Strawn","year":"2017","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.10.013_bib63","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1089\/cap.2015.0192","article-title":"Placebo response in pediatric anxiety disorders: implications for clinical trial design and interpretation","volume":"26","author":"Dobson","year":"2016","journal-title":"J\u00a0Child Adolesc Psychopharmacol"},{"key":"10.1016\/j.jaac.2019.10.013_bib64","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1176\/appi.ajp.2017.16091059","article-title":"Antidepressant efficacy for depression in children and adolescents: industry- and NIMH-funded studies","volume":"174","author":"Walkup","year":"2017","journal-title":"Am J Psychiatry"}],"container-title":["Journal of the American Academy of Child & Adolescent Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856719321136?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0890856719321136?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T14:29:49Z","timestamp":1760192989000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0890856719321136"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,11]]},"references-count":63,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2020,11]]}},"alternative-id":["S0890856719321136"],"URL":"https:\/\/doi.org\/10.1016\/j.jaac.2019.10.013","relation":{},"ISSN":["0890-8567"],"issn-type":[{"value":"0890-8567","type":"print"}],"subject":[],"published":{"date-parts":[[2020,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Antidepressant Tolerability in Pediatric Anxiety and Obsessive-Compulsive Disorders: A Bayesian Hierarchical Modeling Meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Academy of Child & Adolescent Psychiatry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jaac.2019.10.013","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a92019 American Academy of Child and Adolescent Psychiatry","name":"copyright","label":"Copyright"}]}}